Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.

Saved in:
Bibliographic Details
Title: Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Authors: Datoo MS; Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK., Dicko A; Clinical Research Unit of Bougouni-Ouelessebougou, Malaria Research and Training Centre, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali., Tinto H; Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso., Ouédraogo JB; Institut des Sciences et Techniques (INSTech), Bobo-Dioulasso, Burkina Faso., Hamaluba M; Kenya Medical Research Institute Centre for Geographical Medicine Research-Coast (KEMRI-CGMRC), Kilifi, Kenya; Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine, Oxford, UK., Olotu A; Ifakara Health Institute, Bagamoyo Research and Training Centre, Bagamoyo, Tanzania., Beaumont E; London School of Hygiene and Tropical Medicine, London, UK., Ramos Lopez F; Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK., Natama HM; Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso., Weston S; Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK., Chemba M; Ifakara Health Institute, Bagamoyo Research and Training Centre, Bagamoyo, Tanzania., Compaore YD; Institut des Sciences et Techniques (INSTech), Bobo-Dioulasso, Burkina Faso., Issiaka D; Clinical Research Unit of Bougouni-Ouelessebougou, Malaria Research and Training Centre, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali., Salou D; Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso., Some AM; Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso., Omenda S; Kenya Medical Research Institute Centre for Geographical Medicine Research-Coast (KEMRI-CGMRC), Kilifi, Kenya., Lawrie A; Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK., Bejon P; Kenya Medical Research Institute Centre for Geographical Medicine Research-Coast (KEMRI-CGMRC), Kilifi, Kenya., Rao H; Serum Institute of India, Pune, India., Chandramohan D; London School of Hygiene and Tropical Medicine, London, UK., Roberts R; Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK., Bharati S; Serum Institute of India, Pune, India., Stockdale L; The Jenner Institute Laboratories, University of Oxford, Oxford, UK., Gairola S; Serum Institute of India, Pune, India., Greenwood BM; London School of Hygiene and Tropical Medicine, London, UK., Ewer KJ; The Jenner Institute Laboratories, University of Oxford, Oxford, UK., Bradley J; London School of Hygiene and Tropical Medicine, London, UK., Kulkarni PS; Serum Institute of India, Pune, India., Shaligram U; Serum Institute of India, Pune, India., Hill AVS; Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK; The Jenner Institute Laboratories, University of Oxford, Oxford, UK. Electronic address: adrian.hill@ndm.ox.ac.uk.
Corporate Authors: R21/Matrix-M Phase 3 Trial Group
Source: Lancet (London, England) [Lancet] 2024 Feb 10; Vol. 403 (10426), pp. 533-544. Date of Electronic Publication: 2024 Feb 01.
Publication Type: Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-547X
DOI:10.1016/S0140-6736(23)02511-4